发明申请
US20090074752A1 Surrogate Therapeutic Endpoint For Anti-CTLA-4 Based Immunotherapy Of Disease
有权
用于抗CTLA-4的免疫治疗疾病的替代治疗终点
- 专利标题: Surrogate Therapeutic Endpoint For Anti-CTLA-4 Based Immunotherapy Of Disease
- 专利标题(中): 用于抗CTLA-4的免疫治疗疾病的替代治疗终点
-
申请号: US12259075申请日: 2008-10-27
-
公开(公告)号: US20090074752A1公开(公告)日: 2009-03-19
- 发明人: Israel Lowy , Geoffrey M. Nichol
- 申请人: Israel Lowy , Geoffrey M. Nichol
- 申请人地址: US NJ Princeton
- 专利权人: Medarex, Inc.
- 当前专利权人: Medarex, Inc.
- 当前专利权人地址: US NJ Princeton
- 主分类号: A61K39/395
- IPC分类号: A61K39/395
摘要:
The present invention provides a method of treatment using human sequence antibodies against human CTLA-4. In particular, methods of treating cancer are provided.